Pulse Biosciences (PLSE) heads into its November 5 earnings release with expectations for a quarterly loss of $0.35 per share, while forecasts point to a sharp year over year jump in revenue.
The share price of Pulse Biosciences has moved sharply over 2026, with a year-to-date share price return of 295.07% and a 90-day share price return of 38.59%. The 1-year total shareholder return of 215.07% and very large 3-year total shareholder return indicate that investors have been steadily reassessing both its growth potential and risk profile ahead of the earnings release.
Scan how Pulse Biosciences compares with other fast moving healthcare stocks by reviewing the hand picked 33 healthcare AI stocks that are also reacting to earnings expectations and clinical momentum.
After a move this steep in Pulse Biosciences, the puzzle is simple. Is the recent run already pricing in most of the story, or does the current valuation still leave meaningful upside on the table?
Most Popular Narrative: 15% Undervalued
At a last close of $52.90, Pulse Biosciences trades below the most followed fair value estimate of about $62.33. This frames current enthusiasm as a discount rather than a premium and places more emphasis on whether the growth story holds up.
Advancing clinical programs for the nPulse cardiac surgical clamp and nPulse 360 Catheter in atrial fibrillation, including FDA IDE approval, breakthrough designation, and expanding EU feasibility data, creates a path to entry in a high value EP and cardiac surgery market that can expand the company’s addressable revenue base and long term earnings power.
See why 3 investors see Pulse Biosciences as 15% undervalued.
Result: Fair Value of $62.33 (UNDERVALUED)
Still, the bullish Pulse Biosciences story quickly weakens if pivotal nsPFA trials underperform or if high cash use and GAAP losses persist longer than analysts expect.
Find out about the key risks to this Pulse Biosciences narrative.
Another View on Pulse Biosciences Valuation
That analyst driven fair value of $62.33 for Pulse Biosciences runs into a very different message from the SWS DCF model. On projected future cash flows, the shares are valued at $16.57, which implies the current $52.90 price is rich rather than cheap. When two frameworks clash this sharply, which one do you trust more with your capital?
Look into how the SWS DCF model arrives at its fair value: Look into how the SWS DCF model arrives at its fair value.
Next Steps
Sentiment around Pulse Biosciences is split between excitement and caution, and that tension is exactly where thoughtful investors can do their best work. Act while the information is fresh, review the available numbers, stress test your own thesis, then weigh the 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond Pulse Biosciences?
If Pulse Biosciences has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that line up better with your risk and return goals.
- Target potential mispricing by reviewing the 34 high quality undervalued stocks that combine stronger fundamentals with prices that may not fully reflect their underlying numbers.
- Prioritize resilience by scanning the 29 resilient stocks with low risk scores where balance sheets and risk scores work together to reduce the chance of nasty surprises.
- Spot early opportunities by checking the 19 high quality undiscovered gems that pair quality financials with lower market attention before everyone else arrives.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com